Home PageIn Licensing OpportunitiesSucraid

SUCRAID®
(sacrosidase) oral solution

Status: U.S. FDA-Approved, U.S. Orphan Drug

About Sucrase Isomaltase Disease (SID)

Patients with either Congenital Sucrase Isomaltase Disease (CSID) or Acquired Sucrase Isomaltase Disease (ASID) lack the ability to produce sucrase, an enzyme normally secreted in the small intestine and required to digest sucrose. As such, they experience chronic, frequent, explosive, watery diarrhea (with pain, gas, nausea and vomiting).

However, as there have been no pharmacologic therapies for SID before Sucraid®, physicians have not traditionally tested for SID in patients presenting such symptoms. SID is most often misdiagnosed (and, therefore, unsuccessfully treated) as Crohn’s Disease, IBS or lactose intolerance.

The Sucraid® Therapeutic Challenge

Sucraid® is the only available enzyme replacement therapy for SID, and is a simple solution for a difficult disease. Although it is only FDA-approved for CSID currently, studies demonstrate its effectiveness in treating acquired forms of the disease as well, which have much higher incidence rates.

Sucraid® can be administered as a therapeutic challenge for any patient whose severe, chronic, IBS-like symptoms have been unresponsive to treatment. If a patient is, indeed, sucrase-deficient, he or she will respond to the challenge and should be asymptomatic within approximately one week.